Literature DB >> 22715208

Global burden of hepatitis C: considerations for healthcare providers in the United States.

Francisco M Averhoff1, Nancy Glass, Deborah Holtzman.   

Abstract

An estimated 2%-3% of the world's population is living with hepatitis C virus (HCV) infection, and each year, >350 000 die of HCV-related conditions, including cirrhosis and liver cancer. The epidemiology and burden of HCV infection varies throughout the world, with country-specific prevalence ranging from <1% to >10%. In contrast to the United States and other developed countries, HCV transmission in developing countries frequently results from exposure to infected blood in healthcare and community settings. Hepatitis C prevention, care, and treatment programs must recognize country-specific epidemiology, which varies by setting and level of economic development. Awareness of the global epidemiology of HCV infection is important for US healthcare providers treating foreign-born patients from countries where HCV infection is endemic and for counseling patients who travel to these countries. Countries with a high burden of HCV infection also would benefit from establishing comprehensive prevention, care, and treatment programs.

Entities:  

Mesh:

Year:  2012        PMID: 22715208     DOI: 10.1093/cid/cis361

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  131 in total

Review 1.  Current and Future Burden of Chronic Nonmalignant Liver Disease.

Authors:  Prowpanga Udompap; Donghee Kim; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-17       Impact factor: 11.382

2.  Newer therapeutics for hepatitis C.

Authors:  Bhawna Poonia; Shyam Kottilil
Journal:  Ann Transl Med       Date:  2016-01

Review 3.  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Authors:  R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland
Journal:  Expert Rev Clin Pharmacol       Date:  2013-05       Impact factor: 5.045

Review 4.  Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective.

Authors:  Karina Salvatierra; Sabrina Fareleski; Alicia Forcada; F Xavier López-Labrador
Journal:  World J Virol       Date:  2013-02-12

5.  Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong.

Authors:  X Li; N S Chan; A W Tam; I F N Hung; E W Chan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-05-17       Impact factor: 3.267

Review 6.  Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer.

Authors:  Jessica Brownell; Stephen J Polyak
Journal:  Clin Cancer Res       Date:  2013-01-15       Impact factor: 12.531

7.  Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Authors:  Lisa N Wasilewski; Stuart C Ray; Justin R Bailey
Journal:  J Gen Virol       Date:  2016-09-21       Impact factor: 3.891

8.  Trends in liver cancer mortality in the United States: Dual burden among foreign- and US-born persons.

Authors:  Meheret Endeshaw; Benjamin D Hallowell; Hilda Razzaghi; Virginia Senkomago; Matthew T McKenna; Mona Saraiya
Journal:  Cancer       Date:  2018-11-27       Impact factor: 6.860

Review 9.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  Modulation of hepatitis C virus genome encapsidation by nonstructural protein 4B.

Authors:  Qingxia Han; David Manna; Kerry Belton; Richard Cole; Kouacou V Konan
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.